Abstract: Blastic plasmacytoid dendritic cell neoplasm is a rare clinicopathologic entity, characterized by strong skin tropism and a poor prognosis. The diagnosis is generally made by skin biopsy with appropriate immunohistochemical studies. To identify potential biological prognostic factors for blastic plasmacytoid dendritic cell neoplasm, we performed an extended clinico-immunohistochemical study on a series of 91 welldocumented cases collected since 1995 by the French Study Group on Cutaneous Lymphomas. Skin biopsies were analyzed using a panel of 12 immunohistochemical markers (CD4, CD56, CD123, CD303, TCL1, CD68, CD2, CD7, TdT, Ki-67, S100, and MX-1). The results were correlated with survival. The 5 most characteristic markers of this entity (CD4, CD56, CD123, CD303, and TCL1) were expressed simultaneously in only 46% of patients. However, when 4 markers were expressed the diagnosis could still be reliably made without resorting to any additional stains. Expression of TdT and/or S100 correlated with varying degrees of maturation. Statistical survival analyses showed that CD303 expression and high proliferative index (Ki-67) were significantly associated with longer survival.
B lastic plasmacytoid dendritic cell neoplasm (BPDCN) as defined in the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissue is a rare entity characterized by a malignant proliferation of blastic plasmacytoid dendritic cells (PDCs). 1 A highly malignant disease with a poor prognosis, it is clinically characterized by strong cutaneous tropism and a leukemic phase, either present at initial diagnosis (approximately 50% of cases) or in the subsequent course of the disease. [2] [3] [4] Initially, BPDCN was defined phenotypically by the coexpression of CD4 and CD56 antigens and the absence of any common myeloid, T-lymphoid, B-lymphoid, and NK-lymphoid lineage markers. 1 Recent phenotypic advances and the availability of antibodies 5 that recognize more specific PDCrelated antigens (CD123, CD303 [BDCA-2], TCL1) now allow a more ready diagnosis of BPDCN. 2, 6 Several clinical and molecular studies have been conducted in the quest for objective prognosis criteria, with results essentially suggesting the need for further investigation. [7] [8] [9] [10] [11] We therefore undertook this study of a large cohort of 91 patients with the aim of identifying such potential criteria.
MATERIALS AND METHODS

Patients
A total of 91 patients with BPDCN identified in the French Study Group on Cutaneous Lymphoma database since 1995 were included in the study. From 1995 to 2008 these patients were diagnosed as having "CD4 + CD56 + hematodermic neoplasms" or "blastic NK-cell lymphomas" and from 2008 as having BPDCN. For each patient, we obtained general clinical data, including previous medical history, staging at diagnosis, and follow-up data for survival studies (Table 1) . In all cases, histologic and phenotypical characteristics were in keeping with the diagnosis of BPDCN.
Histology and Immunohistochemistry
In all patients, the initial diagnosis of BPDCN was made by skin biopsy. Slides and paraffin blocks of formalin-fixed skin biopsies of all cases were obtained by one of the authors (T.P.) to perform extended immunohistochemical studies using a panel of 12 antibodies (Table 2) . Hematoxylin and eosin staining of each case was performed. Immunohistochemical analysis was performed on paraffin sections using a Benchmark automate (Ventana Medical system, Illkich, France).
Statistical Methods
Overall survival was measured for all patients using the date of diagnosis to death or to last follow-up. Statistical analyses were performed using IBM SPSS Statistics Version 19 for both the univariate and multivariate methods. Differences were estimated by the Fisher exact test or the w 2 test (statistical significance for P < 0.05). Differences between means of quantitative variables were tested with the Student t test. All survival data were analyzed using the Kaplan-Meier method.
RESULTS
Clinical Findings
Clinical data for 85 of the 91 patients in this series have been previously reported. 12 A summary is given in Table 1 . The study group contained 61 male and 30 female patients (sex ratio: M/F: 2.03), ranging in age from 8 to 103 years at the time of diagnosis (mean age: 67.8 y). The skin lesions were brownish to violaceous patches, plaques, or tumors. Clinical presentation varied widely from a single lesion (Fig. 1A ) to disseminated cutaneous disease (Fig. 1B) . Sixty-six patients (74.2%) presented initially with 1 or 2 isolated cutaneous nodules only.
Staging investigations included blood analysis, bone marrow (BM) biopsy, and computed tomography scanning of the chest, abdomen, and pelvis. Results of initial staging studies were unavailable for 8 patients. Two patients died before staging was completed, and 2 others refused BM aspiration. Initial staging was negative in 28 of 83 (33.7%) patients, whereas 55 (61.1%) patients had BM, lymph node, and/or blood involvement. Nine patients (10%) had central nervous system involvement. Mean survival was 15.2 months (95% confidence interval, 12.2-17.2). Only 14 patients (17.3%) were still alive when the study was performed (survival ranged from 6 mo to 6 y).
Immunohistochemical Findings
In each case, hematoxylin and eosin staining confirmed the presence of a cutaneous infiltration of tumor cells morphologically in keeping with BPDCN. The immunohistochemical findings are reported in Table 2 (overall) and Table 3 (each patient). In 3 cases, further immunohistochemical study was impossible because of an absence of tissue in the paraffin blocks (patients 21, 47, and 85). In the remaining cases, the slides received were adequate for interpretation. Except for TdT and Ki-67, each antibody was reported as positive (+), negative (À) (with an arbitrary threshold of 30% positive tumor cells), or not interpretable, the latter due to lack of tissue on the slide or in the block. When positive, TdT and Ki-67 results were reported as the percentage of positive cells, range 1% to 100% (Table 3) .
No cases were totally negative with Ki-67 staining. The results of Ki-67 were further divided into 3 groups for statistical analyses: group 1: low expression (estimated 1% to 33% of cells staining positively); group 2: medium expression (estimated 34% to 66%); and group 3: high expression (estimated 67% to 100%).
When the 5 main markers for the diagnosis of BPDCN (CD4, CD56, CD123, CD303, and TCL1) were positive, their positivity was unequivocal, as essentially 100% of tumor cells were stained. However, we found that only 46 patients (50%) showed simultaneous expression of these 5 markers. CD4 was positive in 98% of cases, CD56 in 92%, CD123 in 97%, CD303 ( Fig. 2A) in 63%, and TCL1 in 99%.
Concerning the other markers, MX-1 (MX-A) (Fig. 2B ) was positive in 65% of cases, CD68 (KP1) in 84%, CD2 in 37%, CD7 in 11%, TdT in 19%, and S100 in 32% (Fig. 2C ). For CD68 (KP1), cases with very small and/or faint "dots" were also considered positive. Staining for CD2, CD7, and S100 was almost always heterogenous and focal. The proliferative index marker Ki-67 could be analyzed in 79 cases: 41 (52%) had a low proliferative index (1% to 33%), 21 (27%) had a medium index (34% to 66%), and 17 (21%) had a high index (67% to 100%).
Statistical Findings
The w 2 test revealed a significant correlation between sex and S100 positivity (P = 0.017), with S100 positivity occurring less often in male patients. In addition, a pattern of conegativity between S100 and TdT was found (P = 0.021). No other associations were demonstrated regarding clinical data, initial staging, sex, age, and marker expression.
The Student t test showed a link between CD303 (BDCA-2) and overall survival: patients with CD303-positive tumors had increased overall survival compared with those whose tumors were CD303 negative (P = 0.004) (Fig. 3) . This was confirmed by KaplanMeier survival analysis (P = 0.014) (Fig. 4) . Furthermore, better survival was observed in patients with a proliferation index, as measured by Ki-67, Z67% (P = 0.036) (Fig. 5) .
DISCUSSION
BPDCN, previously named blastic NK-cell lymphoma 13 and CD4 + CD56 + hematodermic neoplasm, 14 is phenotypically characterized by CD4 and CD56 coexpression, the expression of PDC markers (CD123, CD303, TCL1), and the absence of any specific myeloid, T-lymphoid, B-lymphoid, or NK-lymphoid lineage markers. 1 Immunohistochemical study is thus essential for the diagnosis BPDCN. There is presently no formal immunohistochemical definition of the disease, but in light of the results of the present study we believe a confident diagnosis can be made when 4 of the 5 principle markers (CD4, CD56, CD123, CD303, and TCL1) are expressed by tumor cells. When only CD4, CD56, and CD123 are positive and CD303 and TCL1 are negative, as in patient 5, the differential diagnosis should be carefully considered as CD123 is also frequently expressed in acute myeloid leukemia. 15 In such cases, it is important to demonstrate myeloid marker negativity. For patients with blood involvement, a leukemic cell scoring scheme has been proposed on the basis of the flow cytometry study by Garnache-Ottou et al. 16 First scored is the CD4 + , CD56 +/ À , MPO neg , cCD3 neg , cCD79a neg , and CD11c neg profile and then the CD123 high , BDCA-2, and BDCA-4 profile. However, this scoring scheme is not directly applicable to histologic diagnosis. CD4 + /CD56 + coexpression is important by definition, but sometimes CD4 or CD56 expression can be lacking. In our series, CD4 was negative in 2 cases (2%) and CD56 in 6 (7%). There were no double-negative cases. When CD56 is absent, one should be careful to exclude a mature PDC proliferation. 6 Loss of CD4 or CD56 expression is in accordance with other published series: Ascani et al 17 À cases with 1 double-negative case. These results can be explained by inherent immunophenotypical variations of the neoplastic cells or by failure to detect phenotype expression on formalin-fixed, paraffin-embedded samples, as suggested by Ascani et al. 17 CD68 expression by tumor cells has been reported in about 50% of cases. 4, 6, 20, 21 In our experience CD68 expression has been found in 84% of cases; however, it is noteworthy that we include cases with very faint positivity in the form of small dots, which might explain this variation. In contrast, in the series of pediatric cases reported by Jegalian et al, 22 using the same clone as us, CD68 was negative in all but 1 case.
Expression of TdT, a marker of precursor hematopoietic cells, can be quite variable. TdT was positive in 19% of cases in our study, whereas it was positive in 61.1% of cases examined by Cota et al. 4 TdT expression has been proposed as predictive of a relatively favorable outcome by Jaye et al. 9 They observed in a study of 19 cases an inverse correlation between TdT and BDCA-2 (CD303) expression. This result was not confirmed in our study.
CD303 (BDCA-2) is a member of the growing family of type II C-type lectine receptors, including DC-SIGN, Dectin-1, and DCAL-2, which influence DC function upon ligand binding. 23 It is specifically expressed on human PDCs, 24 in which it serves as an endocytotic receptor and influences maturation and IFN-I secretion. BDCA-2 in PDCs is regulated as a maturation marker, with increased expression as PDC precursors mature and differentiate in the BM and blood. They mediate potent inhibition of induction of INF-I in PDCs. 24 Immunohistochemical expression of BDCA-2 by tumor cells in BPDCN was initially demonstrated by Jaye et al. 9 In our study, we found positivity of BDCA-2 in 63% of cases. In contrast to the findings of Jaye and colleagues, we observed a better prognosis in BDCA-2-positive cases. We found no statistical correlation of survival with the expression of TdT and/or CD7, nor with the expression of BDCA-2 and MX-1 (MX-A), the latter being a surrogate for INF-I. Jaye and colleagues have developed the concept of a spectrum of maturation within the group of BPDCNs. In their study, they suggested that BDCA-2 + / TdT À cases were more mature with a worse prognosis, and BDCA-2 À /TdT + cases were more immature with a better prognosis. We also believe in this spectrum of maturation, but based rather on the expression profiles of TdT and S100. TdT is a marker of immaturity, whereas S100 is a marker of dendritic cells, which are more mature than PDCs (indeterminate dendritic cells and Langerhans cells). Our analysis revealed 33 cases with TdT and/or S100 positivity. In 24 of these cases, there was a reciprocal exclusion between TdT and S100 (ie, when TdT was positive S100 was negative and when TdT was negative S100 was positive), supporting the notion of subtypes of BPDCN: less mature (TdT + /S100 À ) and more mature (TdT À /S100 + ). However, in 9 cases there was double positivity (TdT + /S100 + ). In those cases, double staining showed that TdT and S100 were expressed by different cells (Fig. 2D) , suggesting different degrees of maturation within the same tumor. We found no differences among these 3 subtypes in terms of prognosis. However, Jegalian et al 22 showed in their series of pediatric cases S100 expression being associated with a better prognosis than is seen in adult cases.
The cell proliferation marker Ki-67 is variably expressed in BPDCN. Interestingly, our study showed that those patients with tumors with a high proliferative index (Z67%) had a statistically significant better survival. At first glance, this result is surprising as high proliferative tumors are in general considered more aggressive. It may be that cases with a very high proliferative index have a better response to antimitotic chemotherapy, which may prolong survival.
CONCLUSIONS
BPDCN is a rare disease with a poor prognosis. Effective therapies have yet to be established, and no reliable prognostic factors have been discovered. From this large series of 91 cases, potential immunohistochemical prognostic factors have now been identified: BDCA-2 (CD303) and Ki-67. Subgroups of tumors may be identified on the basis of the level of maturation toward dendritic cells by evaluating TdT and S100 expression, but these distinctions for now have no prognostic implications.
